

## Supporting Information

**Title** Cell-templated Supported Lipid Bilayers for T Cell Activation

*Brynn R. Olden, Caleb R. Perez, Ashley L. Wilson, Ian I. Cardle, Yu-Shen Lin, Bryan Kaehr, Joshua A. Gustafson, Michael C. Jensen, Suzie H. Pun\**

## Supporting Tables

**Table S1.** Molar composition of lipid bilayers

<b>Molar %</b>	<b>Liquid Crystalline (Fluid)</b>	<b>Ordered Gel (Stationary)</b>
77.5	DOPC ( $T_m = -17^\circ\text{C}$ )	DSPC ( $T_m = 55^\circ\text{C}$ )
20	Cholesterol	Cholesterol
0.02-2	DSPE-PEG-Biotin	DSPE-PEG-Biotin
0.5-2.48	18:1 PEG-2000 PE	18:0 PEG-2000 PE

**Table S2.** Size and polydispersity of liposomes

<b>Formulation</b>	<b>Z-average diameter (nm)</b>	<b>PDI</b>
DOPC 2%	86.91	0.251
DOPC 0.2%	104.7	0.361
DOPC 0.02%	87.61	0.337
DSPC 2%	81.13	0.172
DSPC 0.2%	81.22	0.161
DSPC 0.02%	93.74	0.213

**Table S3.** Antibody clones and vendors for intracellular cytokine staining (ICCS) panel

<b>Panel: ICCS</b>	<b>Clone</b>	<b>Dye</b>	<b>Vendor</b>
Live/Dead	N/A	BD Horizon Fixable Viability Stain 520	BD Biosciences
CD4	SK3	APC	Biolegend
CD8	SK1	PacBlue	Biolegend
4-1BB	4B4-1	PE	Biolegend
TNF $\alpha$	MAb11	BUV395	BD Biosciences
IFN $\gamma$	4S.B3	BV786	BD Biosciences
IL-2	MQ1-17H12	PE-Cy7	Biolegend

**Table S4.** Antibody clones and vendors for outgrowth panel

<b>Panel:</b>	<b>Clone</b>	<b>Dye</b>	<b>Vendor</b>
---------------	--------------	------------	---------------

<b>Outgrowth</b>			
Live/Dead	N/A	Zombie NIR Fixable Viability Stain	Biologend
CD3	HIT3a	PE	Biologend
CD4	RPA-T4	APC	Biologend
CD8	RPA-T8	FITC	Biologend

**Table S5.** Antibody clones and vendors for differentiation panel

<b>Panel: Differentiation</b>	<b>Clone</b>	<b>Dye</b>	<b>Vendor</b>
Live/Dead	N/A	BD Horizon Fixable Viability Stain 520	BD Biosciences
CD4	OKT4	PE-Dazzle594	Biologend
CD8	SK1	PacBlue	Biologend
CD45RA	HI100	BV785	Biologend
CD62L	DREG-56	PE	Biologend
PD-1	EH12.2H7	BV711	Biologend
CCR7	150503	BUV395	BD Biosciences

**Table S6.** Summary of statistical analysis on aAPC design parameters and T cell response

	<b>Antibody Density</b>	<b>Lipid</b>	<b>Shape</b>
<b>Outgrowth</b>	p<0.0001, positive linear trend	p<0.0001, DOPC>DSPC	p=0.34
<b>CD4/CD8 Ratio</b>	p=0.21	p=0.0035, DOPC>DSPC	p<0.0001, HeLa>RBC>uSphere
<b>CD4<sup>+</sup> Differentiation (CD45RA<sup>+</sup>/CD62L<sup>+</sup>)</b>	p=0.0016, positive linear trend	p=0.15	p=0.0013, RBC>uSphere
<b>CD8<sup>+</sup> Differentiation (CD45RA<sup>+</sup>/CD62L<sup>+</sup>)</b>	p=0.011, positive linear trend	p=0.037, DSPC>DOPC	p<0.0001, RBC≈HeLa>uSphere
<b>PD-1<sup>+</sup>, CD4<sup>+</sup></b>	p=0.13	p=0.49	p<0.001, uSphere>HeLa≈RBC
<b>PD-1<sup>+</sup>, CD8<sup>+</sup></b>	p=0.14	p=0.004, DSPC>DOPC	p=0.32

Supporting Figures




Figure S1. Gating strategy for ICCS flow analysis




Figure S2. Gating strategy for outgrowth flow analysis







Figure S3. Gating strategy for differentiation flow analysis




**Figure S4.** 72-hour microsphere particle activation. (a) Basal cytokine production and (b) 4-1BB expression in CD4<sup>+</sup> and CD8<sup>+</sup> T cells co-cultured with microsphere activation particles (n = 1).




**Figure S5.** Ratio of CD4<sup>+</sup> to CD8<sup>+</sup> T cells after 9-day outgrowth. Data represented as mean  $\pm$  SD (n = 4 biological replicates; paired one-way ANOVA with Dunnett’s multiple comparisons test, \*P < 0.05).




**Figure S6.** CD4<sup>+</sup> T cell differentiation at day 12 post-stimulation. Data are shown as mean of 3 independent experiments with cells from 3 donors (error bars omitted for legibility, paired two-way ANOVA with Bonferroni’s multiple comparisons test, ns = not significant).



**Figure S7.** CD8<sup>+</sup> T cell PD-1 expression at day 12 post-stimulation. Data are shown as mean of 3 independent experiments with cells from 3 donors (Paired one-way ANOVA with Tukey's multiple comparisons test, ns = not significant, P = 0.33).




**Figure S8.** CD4<sup>+</sup> T cell PD-1 expression at day 12 post-stimulation. Data are shown as mean of 3 independent experiments with cells from 3 donors (Paired one-way ANOVA with Tukey's multiple comparisons test, ns = not significant, P = 0.40).




**Figure S9.** (a) Fluorescence-minus-one (FMO) gating and (b) DynaBeads control gating of CCR7<sup>+</sup> cells in live cell, CD4<sup>+</sup>, and CD8<sup>+</sup> T cell populations of three independent donors.




(a)



(b)



(c)



**Figure S10.** Percent of population that is CCR7<sup>+</sup> of (a) live cells, (b) CD8<sup>+</sup> T cells, and (c) CD4<sup>+</sup> T cells. Data represented as mean and individual data points of three independent donors with each symbol representing a different donor.